Integrating AI into diagnostic pathways improves diagnosis and clinical decision-making in heart failure with preserved ejection fraction (HFpEF)

ultromics-echogo-core.jpg

Company: Ultromics Product: EchoGo Core


External validation of artificial intelligence for detection of heart failure with preserved ejection fraction

Nature Communications, 2025

Abstract

Artificial intelligence (AI) models to identify heart failure (HF) with preserved ejection fraction (HFpEF) based on deep-learning of echocardiograms could help address under-recognition in clinical practice, but they require extensive validation, particularly in representative and complex clinical cohorts for which they could provide most value. In this study enrolling patients with HFpEF (cases; n = 240), and age, sex, and year of echocardiogram matched controls (n = 256), we compare the diagnostic performance (discrimination, calibration, classification, and clinical utility) and prognostic associations (mortality and HF hospitalization) between an updated AI HFpEF model (EchoGo Heart Failure v2) and existing clinical scores (H2FPEF and HFA-PEFF). The AI HFpEF model and H2FPEF score demonstrate similar discrimination and calibration, but classification is higher with AI than H2FPEF and HFA-PEFF, attributable to fewer intermediate scores, due to discordant multivariable inputs. The continuous AI HFpEF model output adds information beyond the H2FPEF, and integration with existing scores increases correct management decisions. Those with a diagnostic positive result from AI have a two-fold increased risk of the composite outcome. We conclude that integrating an AI HFpEF model into the existing clinical diagnostic pathway would improve identification of HFpEF in complex clinical cohorts, and patients at risk of adverse outcomes.

Read full study